HR Mechanism - The Sister-Act Rescue
⭐ Homologous recombination is a high-fidelity, error-free mechanism for repairing double-strand DNA breaks, primarily active in the S and G2 phases of the cell cycle when a sister chromatid is available as a template.
- Repairs double-strand breaks (DSBs), primarily active in the S/G2 phase.
- Uses the undamaged sister chromatid as a perfect template, ensuring a high-fidelity, error-free outcome.

Key Proteins - The Repair Crew
- Damage Sensors & Initiators:
- ATM (Ataxia-Telangiectasia Mutated): A master kinase that detects double-strand breaks (DSBs) and activates the repair cascade through phosphorylation.
- MRN Complex (MRE11-RAD50-NBS1): The first responder. Binds directly to broken DNA ends and helps recruit ATM.
- Mediators & Loaders:
- BRCA1 & PALB2: Act as scaffolds, recruiting the core machinery. PALB2 links BRCA1 to BRCA2.
- BRCA2: Essential for loading the RAD51 recombinase onto the processed single-stranded DNA.
- Core Recombinase:
- RAD51: The central enzyme that forms a filament on ssDNA, enabling the search for homology and subsequent strand invasion.
⭐ Exam Favorite: Mutations in BRCA1 and BRCA2 genes, key mediators of homologous recombination, are strongly associated with hereditary breast and ovarian cancers.
Clinical Correlations - When Good Repair Goes Bad

- Hereditary Breast & Ovarian Cancer (HBOC):
- Mutations in BRCA1 & BRCA2 genes impair HR, conferring a high lifetime risk for breast, ovarian, prostate, and pancreatic cancers.
- Fanconi Anemia:
- Rare genetic disorder with mutations in genes essential for repairing DNA crosslinks, involving the HR pathway.
- Presents with bone marrow failure, physical anomalies, and ↑ cancer risk (AML, squamous cell carcinoma).
- Ataxia-Telangiectasia:
- Mutation in the ATM gene, a kinase that activates HR proteins (e.g., BRCA1).
- Features cerebellar ataxia, telangiectasias, immunodeficiency, and ↑ cancer predisposition (lymphoma, leukemia).
⭐ The concept of synthetic lethality is exploited by PARP inhibitors (e.g., Olaparib). These drugs are particularly effective against cancers with BRCA1/2 mutations because the cell has lost both its major DNA repair pathways, leading to targeted cell death.
HR vs. NHEJ - A Tale of Two Fixes

| Feature | Homologous Recombination (HR) | Non-Homologous End Joining (NHEJ) |
|---|---|---|
| Fidelity | High (Error-free) | Low (Error-prone) |
| Cell Cycle | S/G2 Phase | G1 Phase |
| Template | Sister Chromatid | None |
| Speed | Slow | Fast |
| Key Proteins | BRCA1/2, RAD51 | Ku70/80, DNA-PKcs |
High‑Yield Points - ⚡ Biggest Takeaways
- Homologous Recombination (HR) is a high-fidelity, error-free DNA repair mechanism for double-strand breaks (DSBs).
- It primarily occurs during the late S and G2 phases of the cell cycle, using an undamaged sister chromatid as a template.
- Key proteins essential for HR include BRCA1 and BRCA2.
- Mutations in BRCA1/2 are strongly linked to hereditary breast, ovarian, and prostate cancers.
- PARP inhibitors are synthetically lethal to HR-deficient cells, a key cancer therapy principle.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app